Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently, there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasive colonoscopy. Geneoscopy is changing that. It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications.
Buck Surgical provides surgical technologies that improve patient outcomes and expand access to care. Their patented coupling technology solves anastomotic failures with its novel and efficient method of performing anastomoses.
Impetus Agriculture focuses on developing multiple topical or transgenic insect control products. Products that are safe, effective, and sustainable. Products that are not subject to the same insect resistance that has developed in current commercial products.
SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, it develops a 3D visualization platform using real-time holography of the patient's anatomy and catheter location, over the patients, with the goal of providing the clinician and patient a faster, safer delivery of care. SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, over the patient. The visualization is fully controllable by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission.
Omniose is an early stage biotechnological company developing next-generation conjugate vaccines against infectious diseases using our proprietary in vivo conjugating technology.
Cadre Bioscience aims to accelerate the development of early-stage therapeutics for multiple technology assets.
Healthy Bytes employs registered dietitians. We connect them to employers for their employees who seek medical care for obesity, diabetes, high blood pressure, cardiovascular disease, and orthopedic issues. The employee uses their existing medical benefit to pay for the care of the registered dietitians.
Plastomics is a biotechnology startup that focuses in developing the next generation of crops by using chloroplast genetic engineering. Its technology platform is applicable to different crops and traits. Plastomics provides solutions for the many current industry challenges. The company was founded in 2016 and headquartered in St. Louis, Missouri.
Journeys Metabolic is a digital solution provider filling the gap of metabolic care beyond PCP office. The in-home, interoperable HITRUST 6-month program for obesity and T2 diabetes reversal enables health systems and ACO's to transition to value-based care with no burden no the care team. Based on five years of sustained behavior modification, the physician-developed program uses AI-enabled precision pathways, computer vision of food for education, and proprietary Biosense biomarker of fat oxidation levels. Journeys Metabolic supports shared savings optimization in boht metabolic diseases and nutrition related disorders with nutritional interventions.
Aggio is an information technology company that provides a cloud-based platform to provides solutions in marketing and sales on the agriculture industry. Its platform offers a marketing and sales analytics to help its clients in data-driven decision making by providing data harmonization and visualization.
Impetus Agriculture focuses on developing multiple topical or transgenic insect control products. Products that are safe, effective, and sustainable. Products that are not subject to the same insect resistance that has developed in current commercial products.
Arch Innotek is a biotechnology company that produces natural carotenoid antioxidants by fermentation in yeast. It produces innovative technology to produce high-value natural ingredients for human and animal health by low-cost and sustainable fermentation-based processes.
Omniose is an early stage biotechnological company developing next-generation conjugate vaccines against infectious diseases using our proprietary in vivo conjugating technology.
Kalocyte is a pre-clinical stage healthcare biotech startup company that provides artificial red blood cell substitutes used for trauma care related services. The company develops a demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable, or in short supply. Kalocyte was founded in 2016 and is headquartered in Baltimore, Maryland.
BacterioScan is a precision bench-top system that enables rapid detection and real-time quantification of microbial growth. It eliminates workflow bottlenecks and the inherent inaccuracies of legacy plating procedures. Its technology is helping clinicians personalize medicine for patients, and it’s helping researchers bring new antibiotics to market faster and more economically. The potential applications are far-ranging, offering considerable advantages for any microbiology laboratory that can benefit from rapid detection and real-time quantification of bacterial growth, as well as BacterioScan’s space-saving bench-top footprint and its rapid return on investment.
Start Right commercializes convenient, protein-packed, nutritional breakfast foods. They strive to deliver a high-protein, convenient breakfast that is not only good for customers but also tastes great. Their products include waffles, pancakes, frozen food, waffle sliders, breakfast, protein, and gluten free.
Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University. Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.
Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.
Atomation, founded in Tel Aviv and now with headquarters in Saint Louis, Missouri, is a business-to-business solutions company that uses an innovative Internet of Things (IoT) platform to connect existing, in-field, legacy objects and assets to the internet. Focused on making the data gathered by sensors into useful and actionable information, Atomation solves problems differently with affordable and simple solutions that allow businesses to transform operations and optimize their bottom line.
Plastomics is a biotechnology startup that focuses in developing the next generation of crops by using chloroplast genetic engineering. Its technology platform is applicable to different crops and traits. Plastomics provides solutions for the many current industry challenges. The company was founded in 2016 and headquartered in St. Louis, Missouri.
SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, it develops a 3D visualization platform using real-time holography of the patient's anatomy and catheter location, over the patients, with the goal of providing the clinician and patient a faster, safer delivery of care. SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, over the patient. The visualization is fully controllable by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission.
CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.
S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.
The platform is an all-in-one care coordination tool to enable providers, payers, patients and family collaborate across the care continuum.
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy.
Edison Agrosciences is an agricultural biotechnology company dedicated to developing and commercializing innovative solutions for the production of plant-based industrial materials, with a primary focus on the development of alternative rubber crops. They are engineering yield improvements and the novel production of industrial materials in suitable plant systems. Edison has an emerging IP portfolio covering multiple technical strategies and they are developing strategic partnerships to mitigate the risk of pilot scale crop and product validation. Edison’s strong leadership team has a track record of success in industry.
S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.
Nitrogenics
Seed Round in 2015
Nitrogenics is a plant biotechnology company providing research analysis on nitrogen fixation in crop plants. Nitrogenics' services include data related to plant enzymes that are inserted in the genome of tobacco, enabling researchers to get to research on plants that absorbs nitrogen directly from the atmosphere, rather than from fertilized soil.
Antegrin Therapeutics
Seed Round in 2015
Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.
MedSocket provides a clinical decision support system with a patented 1-Click Decision Support (1-CDS) system and a patented medical search engine (1-Search). The technology was designed by clinicians, with specific attention to their needs and requirements. 1-CDS and 1-Search connect busy, practicing clinicians to evidence-based information quickly and easily. Both technologies have been successfully piloted at the University of Missouri Health System and show potential to improve healthcare decisions, enhance efficiency, decrease healthcare costs, decrease errors and improve patient outcomes. MedSocket was created to improve efficiency and quality of patient care through advanced clinical decision support, information retrieval and knowledge management technologies. Being involved in patient care, Dr. Karl Kochendorfer, inventor of 1-Search and co-inventor of 1-CDS, identified that healthcare providers were constantly in need of quick access to information at the point of care. 1-CDS, the one click decision support tool, and 1-Search, a medical search engine, were created in an effort to alleviate this need. In 2012, Dr. Kochendorfer brought together the business and information science expertise of Matt Botkin and Jayne Williams to form MedSocket.
Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.
Cofactor Genomics is a company focused on predictive immune modeling. They aim to advance precision medicine by overcoming existing barriers. Cofactor facilitates the shift from single-analyte biomarkers to more comprehensive multidimensional biomarkers using health expression models. Their capabilities include molecular, informatic, and database tools, with one of the first CAP-certified clinical RNA sequencing laboratories. This certification helps their partners conduct clinical trials more efficiently and cost-effectively. Their expertise in molecular biology, informatics, and database management enables them to provide high-quality services to the healthcare and pharmaceutical sectors, contributing to medical research and improving patient outcomes.
CLS is a drug discovery company focusing on rational drug design to discover and develop mechanistically novel kinase inhibitors for use in both human and animal health care. CLS’s kinase inhibitors target key signal transduction enzymes involved in the regulation of cancer growth and survival, or in the modulation of chronic inflammation. Unlike many other kinase inhibitor programs, however, CLS is targeting novel binding sites (on kinase targets that have proved challenging) as well as previously “un-drugged” kinases. Driving CLS success in this effort is a team of world-class experts with extensive Pharma experience in kinase inhibitor discovery and development. CLS provides this team with the opportunity to pursue strategies and targets outside Pharma’s traditional focus. In addition, scientific and business collaborations are being established to enable the success of the business. The strategy is to develop and maintain a program pipeline: discover, develop, partner, repeat.
GeneriCo is focused on developing and marketing niche generic pharmaceuticals that have been neglected by mid and large generic companies and also have an embedded drug delivery technology. The combination of neglected, technically challenging formulation, and economic size makes the GeneriCo pipeline not appealing to middle and large competitors, and too complex for tightly focused small generic companies.
Neurolutions seeks to develop a revolutionary platform of devices, based on Brain Computer Interface (BCI) technology, which promise to restore function to patients who are disabled as a result of neurological injury.
CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.
Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
RNAgri designs an innovative technology that produces ribonucleic acid. The company's technology addresses some of the challenges to the mass production of exogenous RNAi-based products using a large scale fermentation process, enabling farmers to protect and improve their crops and cattle. The company was founded in 2011 and is headquartered in St Louis, Missouri.
SynerZ Medical
Seed Round in 2015
SynerZ Medical, Inc. develops medical device for the treatment of obesity and type 2 diabetes. The company was incorporated in 2013 and is based in St. Louis, Missouri.
YourBevCo, LLC is a beverage device company developing a pipeline of innovative, disruptive consumer devices that safely and effectively remove problematic ingredients from beverages that are known to cause allergic or sensitivity reactions.
ImmunoPhotonics develops immunotherapy-based treatments for cancer. A minimally invasive therapeutic cancer vaccine for the treatment of metastatic solid tumors. ImmunoPhotonics has a strategic partnership with Veterinary Cancer Therapeutics, LLC. The company was founded in 2008 and is based in Columbia, Missouri.
Kypha is an early-stage life sciences company developing leading-edge technology and clinically useful products to improve the way autoimmune and inflammatory disorders are monitored and treated. With a core team of nine, plus an extensive network of scientific advisors, clinical collaborators and business mentors, Kypha has leveraged Federal grants and raised more than $3 million in private capital since 2011 to advance its lead diagnostic product – Comp Act Dx – toward FDA clearance and commercial launch in early 2014. Comp Act Dx is a simple yet revolutionary test that quickly measures the level of inflammation in the body – such as that caused by traumatic injury or autoimmune disease – with an unprecedented combination of speed and accuracy. Comp Act Dx is designed to allow superior monitoring of at-risk patients by measuring changes in inflammation in near-real time, thereby aiding medical professionals in making earlier, more effective clinical intervention decisions.
Prostate Management Diagnostics
Series A in 2014
Prostate Management Diagnostics creates tests and develops a fluid-based screening tool. It specializes in the fields of health diagnostics, medical, and healthcare. It was founded in 2014 and headquartered in San Francisco, California.
MedSocket provides a clinical decision support system with a patented 1-Click Decision Support (1-CDS) system and a patented medical search engine (1-Search). The technology was designed by clinicians, with specific attention to their needs and requirements. 1-CDS and 1-Search connect busy, practicing clinicians to evidence-based information quickly and easily. Both technologies have been successfully piloted at the University of Missouri Health System and show potential to improve healthcare decisions, enhance efficiency, decrease healthcare costs, decrease errors and improve patient outcomes. MedSocket was created to improve efficiency and quality of patient care through advanced clinical decision support, information retrieval and knowledge management technologies. Being involved in patient care, Dr. Karl Kochendorfer, inventor of 1-Search and co-inventor of 1-CDS, identified that healthcare providers were constantly in need of quick access to information at the point of care. 1-CDS, the one click decision support tool, and 1-Search, a medical search engine, were created in an effort to alleviate this need. In 2012, Dr. Kochendorfer brought together the business and information science expertise of Matt Botkin and Jayne Williams to form MedSocket.
Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.
ImmunoPhotonics develops immunotherapy-based treatments for cancer. A minimally invasive therapeutic cancer vaccine for the treatment of metastatic solid tumors. ImmunoPhotonics has a strategic partnership with Veterinary Cancer Therapeutics, LLC. The company was founded in 2008 and is based in Columbia, Missouri.
Confluence gathers, filters, combines and presents the pharmaceutical intelligence you need. It turns manual into automatic, risk into reliability and wait into wow. With Confluence you start where it counts: crucial planning and decision-making. Skip the assembly, start with Confluence.
Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.
Tansna Therapeutics is a developer of an oral anticonvulsant agent that reduces seizure frequency in patients with epilepsy. The company was founded in 2010.
BacterioScan is a precision bench-top system that enables rapid detection and real-time quantification of microbial growth. It eliminates workflow bottlenecks and the inherent inaccuracies of legacy plating procedures. Its technology is helping clinicians personalize medicine for patients, and it’s helping researchers bring new antibiotics to market faster and more economically. The potential applications are far-ranging, offering considerable advantages for any microbiology laboratory that can benefit from rapid detection and real-time quantification of bacterial growth, as well as BacterioScan’s space-saving bench-top footprint and its rapid return on investment.
GeneriCo is focused on developing and marketing niche generic pharmaceuticals that have been neglected by mid and large generic companies and also have an embedded drug delivery technology. The combination of neglected, technically challenging formulation, and economic size makes the GeneriCo pipeline not appealing to middle and large competitors, and too complex for tightly focused small generic companies.
Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.
Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating fibrotic diseases. Founded on groundbreaking scientific discoveries and leveraging cutting-edge insight into the molecular drivers of aberrant scarring, Indalo is harnessing the collective experience of a seasoned team of pharmaceutical scientists and executives to tackle some of the most urgent unmet medical needs in the fibrosis space.
Antegrin Therapeutics
Seed Round in 2013
Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.
MediBeacon is an optical diagnostic company providing clinicians with critical information that improve patient care. Its mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological diseases in the human population. Several product concepts in these areas are contained in the MediBeacon Intellectual Property (IP) portfolio. The product pipeline includes real-time kidney function monitoring, a huge leap forward in the world of nephrology. The clinical history and road to FDA and European approvals on this component of the MediBeacon pipeline as well as other developments related to the platform of fluorescent agents and their potential clinical application.
Tansna Therapeutics is a developer of an oral anticonvulsant agent that reduces seizure frequency in patients with epilepsy. The company was founded in 2010.
Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.
CLS is a drug discovery company focusing on rational drug design to discover and develop mechanistically novel kinase inhibitors for use in both human and animal health care. CLS’s kinase inhibitors target key signal transduction enzymes involved in the regulation of cancer growth and survival, or in the modulation of chronic inflammation. Unlike many other kinase inhibitor programs, however, CLS is targeting novel binding sites (on kinase targets that have proved challenging) as well as previously “un-drugged” kinases. Driving CLS success in this effort is a team of world-class experts with extensive Pharma experience in kinase inhibitor discovery and development. CLS provides this team with the opportunity to pursue strategies and targets outside Pharma’s traditional focus. In addition, scientific and business collaborations are being established to enable the success of the business. The strategy is to develop and maintain a program pipeline: discover, develop, partner, repeat.
Pulse Therapeutics is a growing medical technology company headquartered in St. Louis, Mo. The medical developer is advancing the fight against stroke, heart disease, and other conditions with its high-level treatment solutions, which utilize the latest biomedical technology and processes. Pulse’s signature offering, the MED System, was designed to harness magnet-based technology to rapidly dissolve blood clots faster than current modalities. This faster rate of delivery of FDA-approved clot-busting medication could dramatically reduce the number of lives lost each year to stroke, heart disease, and other diseases. This pioneering medical development company was founded by leading physicists Francis “Duke” Creighton and Rogers Ritter. Dr. Creighton, who also serves as Pulse’s chief technical officer, has 20-plus years of expertise in the medical technology industry, specializing in the stroke and cardiovascular sectors. He responsible for 30 patents and is a technology reviewer for the National Cancer Institute, National Science Foundation, and National Institutes of Health. The ground-breaking medical solutions of Pulse Therapeutics continues to attract investors and garner media coverage.
Apertus Pharmaceuticals is an Active Pharmaceutical Ingredient, or API, manufacturing company targeting dosage form manufacturing companies within the pharmaceutical industry. Apertus Pharmaceuticals provides controlled substance APIs, non controlled substance APIs, and intellectual property to the pharmaceutical market. In addition, Apertus Pharmaceuticals utilizes the philosophies of Green Chemistry as outlined by the FDA and will target higher purity standards than those set by the current standard setting authorities. Apertus is led by CEO Rick Ryan, Ph.D. and CSO David Gindelberger, Ph.D.
Kypha is an early-stage life sciences company developing leading-edge technology and clinically useful products to improve the way autoimmune and inflammatory disorders are monitored and treated. With a core team of nine, plus an extensive network of scientific advisors, clinical collaborators and business mentors, Kypha has leveraged Federal grants and raised more than $3 million in private capital since 2011 to advance its lead diagnostic product – Comp Act Dx – toward FDA clearance and commercial launch in early 2014. Comp Act Dx is a simple yet revolutionary test that quickly measures the level of inflammation in the body – such as that caused by traumatic injury or autoimmune disease – with an unprecedented combination of speed and accuracy. Comp Act Dx is designed to allow superior monitoring of at-risk patients by measuring changes in inflammation in near-real time, thereby aiding medical professionals in making earlier, more effective clinical intervention decisions.
Array Bridge provides quality products and services for the pharmaceutical and biotechnology industry. Products include antibody arrays for biosimilar and antibody-drug conjugate (ADC) three-dimensional (3-D) conformational comparability analysis, ELISA kits for Host Cell Proteins including CHO and E. coli-derived biologics. Services include antibody production; Host Cell Protein and binding-based bioassay method qualification and validation; 1-D and 2-D gel analysis of process-related impurities; Western Blot analysis of HCPs; Residual DNA and Protein A analysis.
RNAgri designs an innovative technology that produces ribonucleic acid. The company's technology addresses some of the challenges to the mass production of exogenous RNAi-based products using a large scale fermentation process, enabling farmers to protect and improve their crops and cattle. The company was founded in 2011 and is headquartered in St Louis, Missouri.
Companion Pharma
Seed Round in 2012
Companion Pharma is an animal health product development company that will develop innovative new formulations of drugs for use under prescription in companion animals. Companion will specifically target companion animal disease indications that have a high unmet treatment need and will provide 'pet friendly' drugs that are proven to work safely in the target species, are formulated in a way to provide ease of administration and are available in doses that meet the needs of the highly variable weight profile of companion animal pets.
ARTA Bioscience
Grant in 2012
ARTA Bioscience, Inc is developing new therapeutics for prostate cancer and inflammatory diseases. Current treatments for prostate cancer are insufficient and the disease is the second leading cause of cancer deaths among American men. ARTA's technology involves an entirely different approach to combating disease compared to traditional treatments. In addition to prostate cancer, the company's technologies may be used to target other important proteins in the nuclear receptor class. The company has established operations at the BioGenerator Accelerator Labs. ARTA's technology was developed by Dr. Marc Diamond at Washington University.
Mobius Therapeutics is an early-stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. It is awaiting regulatory approval, with additional product applications in earlier stages of development.
Confluence Discovery Technologies is a drug discovery contract research organization (CRO) providing a variety of technical services including mechanistic enzymology, target validation and characterization, screening and assay development, biomarker development and measurement. The company offers its customers novel approaches to identification of kinase inhibitors along with decades of experience developing clinical candidates for this class. Founders were key scientific leaders in Pfizer's Inflammation Research Unit. Confluence is located at the BioGenerator Accelerator Labs.
Array Bridge provides quality products and services for the pharmaceutical and biotechnology industry. Products include antibody arrays for biosimilar and antibody-drug conjugate (ADC) three-dimensional (3-D) conformational comparability analysis, ELISA kits for Host Cell Proteins including CHO and E. coli-derived biologics. Services include antibody production; Host Cell Protein and binding-based bioassay method qualification and validation; 1-D and 2-D gel analysis of process-related impurities; Western Blot analysis of HCPs; Residual DNA and Protein A analysis.
Pulse Therapeutics is a growing medical technology company headquartered in St. Louis, Mo. The medical developer is advancing the fight against stroke, heart disease, and other conditions with its high-level treatment solutions, which utilize the latest biomedical technology and processes. Pulse’s signature offering, the MED System, was designed to harness magnet-based technology to rapidly dissolve blood clots faster than current modalities. This faster rate of delivery of FDA-approved clot-busting medication could dramatically reduce the number of lives lost each year to stroke, heart disease, and other diseases. This pioneering medical development company was founded by leading physicists Francis “Duke” Creighton and Rogers Ritter. Dr. Creighton, who also serves as Pulse’s chief technical officer, has 20-plus years of expertise in the medical technology industry, specializing in the stroke and cardiovascular sectors. He responsible for 30 patents and is a technology reviewer for the National Cancer Institute, National Science Foundation, and National Institutes of Health. The ground-breaking medical solutions of Pulse Therapeutics continues to attract investors and garner media coverage.
PixelEXX Systems Inc. develops prototype imaging devices for diagnosing cancer. The products include nanoarrays that take images of molecular signals associated with cellular activity. PixelEXX Systems Inc. was founded in 2008 and is based in Saint Louis, Missouri.
APT Therapeutics is a Biotechnology company located in 4041 Forest Park Ave., St. Louis, MO, United States.